结直肠癌标志物粪便检测的研究现状

doi:10.3760/cma.j.cn371439-20201005-00085

摘要/Abstract

摘要：

结直肠癌(CRC)标志物粪便检测主要有以下4种方法:粪便隐血试验、粪便DNA检测、粪便微小RNA检测、粪便具核梭杆菌(Fn)检测。免疫法粪便隐血试验已经被国内外专家共识推荐作为CRC筛查的首选方法。由于粪便DNA检测费用偏高,目前国内尚未进行大样本的人群筛查,被推荐为CRC筛查的第二级检查。粪便微小RNA检测逐渐受到学者的重视。近年来,粪便微生物标志物检测越来越热门,特别是粪便Fn检测,有望成为CRC筛查的微生物指标。

关键词: 结直肠肿瘤, 粪便, 微RNAs, 具核梭杆菌, 粪便隐血试验

Abstract:

There are four methods for fecal detection of colorectal cancer (CRC) markers: fecal occult blood test, fecal DNA test, fecal microRNA test, and fecal fusobacterium nucleatum (Fn) test. Fecal immunochemical test has been recommended by experts at home and abroad as the first choice for CRC screening. Fecal DNA test, due to its high price, has not yet been screened for large samples of people in China, so it is recommended as the second level of CRC screening. Fecal microRNA detection has been paid more and more attention by researchers. In recent years, the detection of fecal microbial markers has become more and more popular, especially fecal Fn detection, which is expected to become a microbial indicator for CRC screening.

Key words: Colorectal neoplasms, Feces, MicroRNAs, Fusobacterium nucleatum, Fecal occult blood test

王阳, 刘芊, 龙辉, 吴清明. 结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.

Wang Yang, Liu Qian, Long Hui, Wu Qingming. Research status of fecal detection for colorectal cancer markers[J]. Journal of International Oncology, 2021, 48(7): 441-444.

参考文献 30

[1]	Zhang L, Cao F, Zhang G, et al. Trends in and predictions of colo-rectal cancer incidence and mortality in China from 1990 to 2025[J]. Front Oncol, 2019, 9:98. DOI: 10.3389/fonc.2019.00098. doi: 10.3389/fonc.2019.00098 pmid: 30847304
[2]	Jin P, Wu ZT, Li SR, et al. Colorectal cancer screening with fecal occult blood test: a 22-year cohort study[J]. Oncol Lett, 2013, 6(2):576-582. DOI: 10.3892/ol.2013.1402. doi: 10.3892/ol.2013.1402
[3]	US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement[J]. JAMA, 2016, 315(23):2564-2575. DOI: 10.1001/jama.2016.5989. doi: 10.1001/jama.2016.5989 pmid: 27304597
[4]	Gong Y, Peng P, Bao P, et al. The implementation and first-round results of a community-based colorectal cancer screening program in Shanghai, China[J]. Oncologist, 2018, 23(8):928-935. DOI: 10.1634/theoncologist.2017-0451. doi: 10.1634/theoncologist.2017-0451
[5]	Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis[J]. Ann Intern Med, 2014, 160(3):171. DOI: 10.7326/M13-1484.
[6]	Katsoula A, Paschos P, Haidich AB, et al. Diagnostic accuracy of fecal immunochemical test in patients at increased risk for colorectal cancer: a meta-analysis[J]. JAMA Intern Med, 2017, 177(8):1110-1118. DOI: 10.1001/jamainternmed.2017.2309. doi: 10.1001/jamainternmed.2017.2309
[7]	Eckmann JD, Ebner DW, Kisiel JB. Multi-target stool DNA testing for colorectal cancer screening: emerging learning on real-world performance[J]. Curr Treat Options Gastroenterol, 2020, In press. DOI: 10.1007/s11938-020-00271-5.
[8]	国家消化系统疾病临床医学研究中心(上海), 国家消化道早癌防治中心联盟, 中华医学会消化内镜学分会, 等. 中国早期结直肠癌筛查流程专家共识意见(2019,上海)[J]. 中华消化内镜杂志, 2019, 36(10):709-719. DOI: 10.3760/cma.j.issn.1007-5232.2019.10.001.
[9]	Niedermaier T, Tikk K, Gies A, et al. Sensitivity of fecal immunochemical test for colorectal cancer detection differs according to stage and location[J]. Clin Gastroenterol Hepatol, 2020, 18(13):2920-2928, e6. DOI: 10.1016/j.cgh.2020.01.025. doi: 10.1016/j.cgh.2020.01.025
[10]	Ladabaum U, Dominitz JA, Kahi C, et al. Strategies for colorectal cancer screening[J]. Gastroenterology, 2020, 158(2):418-432. DOI: 10.1053/j.gastro.2019.06.043. doi: S0016-5085(19)41185-2 pmid: 31394083
[11]	Carethers JM. Fecal DNA testing for colorectal cancer screening[J]. Annu Rev Med, 2020, 71:59-69. DOI: 10.1146/annurev-med-103018-123125. doi: 10.1146/annurev-med-103018-123125 pmid: 31451044
[12]	Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer[J]. Gastroenterology, 2015, 149(5):1177-1190, e3. DOI: 10.1053/j.gastro.2015.06.047. doi: 10.1053/j.gastro.2015.06.047
[13]	Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening[J]. N Engl J Med, 2014, 370(14):1287-1297. DOI: 10.1056/NEJMoa1311194. doi: 10.1056/NEJMoa1311194
[14]	国家药品监督管理局医疗器械技术审评中心. 体外诊断试剂产品注册技术审评报告: 人类SDC2基因甲基化检测试剂盒(荧光PCR法)(CSZ1800035)[R/OL]. ( 2018-11-13) [2019-08-01]. https://www.cmde.org.cn/CL0116/8094.html.
[15]	柏愚, 刘晶, 康倩, 等. 联合检测SDC2和SFRP2甲基化在CRC筛查中的价值[J]. 中华消化内镜杂志, 2019, 36(6):427-432. DOI: 10.3760/cma.j.issn.1007-5232.2019.06.009.
[16]	Liu X, Wen J, Li C, et al. High-yield methylation markers for stool-based detection of colorectal cancer[J]. Dig Dis Sci, 2020, 65(6):1710-1719. DOI: 10.1007/s10620-019-05908-9. doi: 10.1007/s10620-019-05908-9
[17]	Ren A, Dong Y, Tsoi H, et al. Detection of miRNA as non-invasive biomarkers of colorectal cancer[J]. Int J Mol Sci, 2015, 16(2):2810-2823. DOI: 10.3390/ijms16022810. doi: 10.3390/ijms16022810
[18]	Yau TO, Tang CM, Harriss EK, et al. Faecal microRNAs as a non-invasive tool in the diagnosis of colonic adenomas and colorectal cancer: a meta-analysis[J]. Sci Rep, 2019, 9(1):9491. DOI: 10.1038/s41598-019-45570-9. doi: 10.1038/s41598-019-45570-9
[19]	Choi HH, Cho YS, Choi JH, et al. Stool-based miR-92a and miR-144* as noninvasive biomarkers for colorectal cancer screening[J]. Oncology, 2019, 97(3):173-179. DOI: 10.1159/000500639. doi: 10.1159/000500639
[20]	Duran-Sanchon S, Moreno L, Augé JM, et al. Identification and validation of microRNA profiles in fecal samples for detection of colorectal cancer[J]. Gastroenterology, 2020, 158(4):947-957, e4. DOI: 10.1053/j.gastro.2019.10.005. doi: S0016-5085(19)41439-X pmid: 31622624
[21]	《现代消化及介入诊疗》杂志共识专家组. 肠道微生态与大肠癌相关性研究专家共识意见[J]. 现代消化及介入诊疗, 2019, 24(1):105-108. DOI: 10.3969/j.issn.1672-2159.2019.01.032.
[22]	Mira-Pascual L, Cabrera-Rubio R, Ocon S, et al. Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers[J]. J Gastroenterol, 2015, 50(2):167-179. DOI: 10.1007/s00535-014-0963-x. doi: 10.1007/s00535-014-0963-x pmid: 24811328
[23]	Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin Cancer Res, 2017, 23(8):2061-2070. DOI: 10.1158/1078-0432.CCR-16-1599. doi: 10.1158/1078-0432.CCR-16-1599
[24]	Nakatsu G, Li X, Zhou H, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis[J]. Nat Commun, 2015, 6:8727. DOI: 10.1038/ncomms9727. doi: 10.1038/ncomms9727 pmid: 26515465
[25]	Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12):1973-1980. DOI: 10.1136/gutjnl-2015-310101. doi: 10.1136/gutjnl-2015-310101
[26]	Gholizadeh P, Eslami H, Kafil HS. Carcinogenesis mechanisms of Fusobacterium nucleatum[J]. Biomed Pharmacother, 2017, 89:918-925. DOI: 10.1016/j.biopha.2017.02.102. doi: S0753-3322(17)30492-4 pmid: 28292019
[27]	Liang JQ, Wong SH, Szeto CH, et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects[J]. J Gastroenterol Hepatol, 2020, In press. DOI: 10.1111/jgh.15171.
[28]	McQuade JL, Daniel CR, Helmink BA, et al. Modulating the microbiome to improve therapeutic response in cancer[J]. Lancet Oncol, 2019, 20(2):e77-e91. DOI: 10.1016/S1470-2045(18)30952-5. doi: 10.1016/S1470-2045(18)30952-5
[29]	Yachida S, Mizutani S, Shiroma H, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer[J]. Nat Med, 2019, 25(6):968-976. DOI: 10.1038/s41591-019-0458-7. doi: 10.1038/s41591-019-0458-7
[30]	Eklöf V, Löfgren-Burström A, Zingmark C, et al. Cancer-associated fecal microbial markers in colorectal cancer detection[J]. Int J Cancer, 2017, 141(12):2528-2536. DOI: 10.1002/ijc.31011. doi: 10.1002/ijc.31011